Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israele, Tel Aviv-Giaffa
David Sarid
38 anni di esperienza
accreditamenti :
Clinica certificata da :
| Israele | Turchia | Austria | |
| Terapia con Lutetio-177 | da $16,500 | da $8,800 | da $35,000 |
Bookimed non aggiunge costi extra ai prezzi di Terapia con Lutetio-177. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica per la tua Terapia con Lutetio-177 al tuo arrivo.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali in Terapia con Lutetio-177 e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di Terapia con Lutetio-177.
Giorno 1
Giorno 2
Giorno 3
Giorno 4
Giorno 5
Settimana 1-2 post-terapia
Settimana 3-4 post-terapia
Settimana 5-6 post-terapia
Si prega di notare che il caso di ogni paziente è unico e la tempistica può variare.
Il Prof. Merimsky dirige l'Unità di Oncologia Ortopedica presso il Centro Medico Sourasky, specializzandosi in terapie avanzate come il Lutetio-177.
Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).
His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.
He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.
He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.
Esperto leader nella terapia con Lutetium-177 – Il Dr. Raphael integra il profilo genomico all'avanguardia con trattamenti mirati con radionuclidi presso il Sourasky Medical Center.
Il dottore si è laureato all'Università di Grodno, Bielorussia, e ha ottenuto la licenza medica in Israele nel 2000. Specializzandosi in medicina interna e oncologia, il dottore ha completato tirocini nel 10° Dipartimento di Medicina Interna e Oncologia presso il Centro Medico di Tel Aviv, Ichilov. Dal 2015, il dottore è direttore del reparto di ospedalizzazione oncologica nello stesso centro.<\/p>
Con una vasta esperienza come ricercatore primario e secondario, il dottore ha partecipato a studi clinici di prima, seconda e terza fase in oncologia, contribuendo significativamente al campo.<\/p>
La terapia con Lutezio-177 è una radioterapia mirata che utilizza il radioisotopo Lutezio-177 per trattare efficacemente determinati tipi di cancro.
Top Lutetium-177 therapy specialists in Israel lead global cancer care. These experts include Prof. Einat Even-Sapir and Dr. Inna Ospovat at Sourasky Medical Center. They specialize in nuclear medicine. Their training includes fellowships at Oxford and leading London hospitals.
Bookimed Expert Insight: Israeli specialists often hold dual expertise in nuclear medicine and oncology. Dr. Simona Glasberg trained at St. Bartholomew's in London. Prof. David Sarid studied at Oxford. This international training helps them design complex therapy protocols. They manage advanced cases across Tel Aviv, Jerusalem, and Haifa centers.
Patient Consensus: Patients mention feeling confident because doctors explain the PET/CT scans clearly. They note the coordination between the imaging and therapy teams is very smooth. Many say the staff made them feel comfortable during the long treatment hours.
Israeli nuclear medicine experts specialize in Lutetium-177 therapy by targeting specific receptors. Prof. Simona Glasberg at Hadassah Medical Center leads neuroendocrine PRRT. Prof. David Sarid at Sourasky Medical Center focuses on prostate PSMA therapy. These doctors work in multidisciplinary teams for precise treatment.
Bookimed Expert Insight: Israeli specialists often provide a centralized 'theranostic' approach. Prof. Einat Even-Sapir and Prof. Zohar Keidar use Ga-68 PET/CT scans first. This confirms the Lutetium-177 will reach the specific tumor targets. Patients receive both diagnosis and therapy at the same facility.
Patient Consensus: Patients note the coordination between the oncology and nuclear departments is smooth. They felt safer knowing the imaging confirmed the therapy would work. Many were surprised by how quickly they could start treatment.
Leading specialists in Lutetium-177 therapy practice at major Israeli centers like Ichilov and Sheba. These experts hold international certifications in nuclear medicine and uro-oncology. They offer advanced PSMA and PRRT programs. Most specialists trained at top institutions in the UK and USA.
Bookimed Expert Insight: Israeli specialists often combine genomic profiling with radionuclide therapy for better results. Dr. Ari Raphael at Ichilov integrates target mapping with Lu-177 for individual cases. This approach helps tailor the radiation dose to the patient's specific tumor markers.
Patient Consensus: Patients mention the hospital staff explains the therapy steps very clearly. They feel comfortable having nuclear medicine and oncology experts working together. Many note that the facilities for radiation therapy stay are quiet and modern.